Plaque Psoriasis Clinical Trial
Official title:
A Phase 2a Study to Evaluate Safety, Tolerability, and Efficacy of PRCL-02 in Patients With Moderate to Severe Chronic Plaque Psoriasis
Verified date | March 2020 |
Source | PRCL Research Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The aim of this study is to evaluate safety, tolerability, and efficacy of PRCL-02 in moderate to severe chronic plaque psoriasis
Status | Completed |
Enrollment | 92 |
Est. completion date | July 8, 2019 |
Est. primary completion date | April 29, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: - Presents with moderate to severe psoriasis vulgaris based on: - Chronic psoriasis vulgaris for at least 6 months - Plaque psoriasis involving at least 10% body surface area (BSA) - Psoriasis Area and Severity Index (PASI) total score of at least 12 - Have at least 2 evaluable plaques located in 2 different body regions. (Also for participants who elect to have plaques biopsied, should be suitable for a total of 4 punch biopsies each, and one lesion, preferably on a region of the body that is not normally exposed (e.g., trunk), should be selected for biopsy) - Have a Static Physician's Global Assessment (sPGA) score of greater than or equal to (=)3 - Are candidates for systemic therapy - Have a body mass index (BMI) within the range of 18 to 40 kilograms per square meter (kg/m2) - Women who are of childbearing potential must agree to use 1 highly effective method of contraception, or a combination of 2 effective methods of contraception for the entirety of the study - Women of non childbearing potential are defined as women who are: - Infertile due to surgical sterilization (hysterectomy, bilateral oophorectomy, or tubal ligation), congenital anomaly such as mullerian agenesis; or - Post-menopausal, defined as either: - A woman at least 50 years of age with an intact uterus, not on hormone therapy, who has had either: cessation of menses for at least 1 year; or at least 6 months of spontaneous amenorrhea with a follicle stimulating hormone greater than (>)40 milli-international units per milliliter (mIU/mL); or - A woman 55 years or older not on hormone therapy, who has had at least 6 months of spontaneous amenorrhea; or - A woman at least 55 years of age with a diagnosis of menopause prior to staring hormone replacement therapy Exclusion Criteria: - Currently enrolled in any other clinical trial involving a study drug or device, or any other type of medical research judged not compatible with this study (Participants in the previous PRCL study (SMAD) will be allowed to be included in this study, provided that they meet all inclusion and none of the exclusion criteria) - Participated in a clinical study within last 30 days - Present with pustular, erythrodermic psoriasis, generalized pustular psoriasis, or acute guttate psoriasis - Have current serious or unstable illnesses including hepatic, renal, gastroenterologic, respiratory, cardiovascular (including a history of ischemic or structural heart disease, conduction system disease or history of clinically significant arrhythmia), endocrinologic, neurologic, psychiatric, immunologic, hematologic, or dermatologic disease - Have a history of clinically significant severe drug allergies or severe post treatment hypersensitivity reactions - Have received inactivated vaccine within 4 weeks prior to dosing in this study, or a live vaccine within the last 3 months - A history of clinically significant opportunistic infection (for example, invasive candidiasis or Pneumocystis pneumonia) - Had symptomatic herpes zoster within last 3 months or other recent or ongoing infection - Present with any of the following laboratory test results: - Positive QuantiFERON®-tuberculosis test - For women, positive serum pregnancy test - Evidence of Human Immunodeficiency Virus (HIV) infection or are positive for HIV antibodies - Positive test for active hepatitis B - Positive of anti-hepatitis C antibody with confirmed presence of hepatitis C virus, or chronic liver disease - Evidence of clinically significant hepatic or renal impairment - Clinically significant ECG (electrocardiogram) abnormalities or personal or family history of heart disease, including: - Confirmed corrected QT interval with Frederica's correction (QTcF) >450 milliseconds (msec) for both men and women - Specific bundle branch blocks, irregular rhythms, history of unexplained syncope, or family history of unexplained death - Are receiving any of the following therapies for psoriasis: - Systemic retinoids within last 12 weeks - Systemic psoriasis therapy, such as psoralen and ultraviolet A (PUVA) light therapy, cyclosporine, corticosteroids, methotrexate, oral retinoids, mycophenolate mofetil, thioguanine, hydroxyurea, sirolimus, azathioprine, or phototherapy (including ultraviolet B or self-treatment with tanning beds or therapeutic sunbathing) within last 4 weeks - Topical psoriasis treatment within last 2 weeks; or - Any biologic agent within the following washout periods: 30 days for anti-tumor necrosis factor (TNF) inhibitors, and 90 days for other agents |
Country | Name | City | State |
---|---|---|---|
Canada | SimcoDerm Medical and Surgical Dermatology | Barrie | Ontario |
Canada | DermEffects | London | Ontario |
Canada | Lynderm Research Inc. | Markham | Ontario |
Canada | SKiN Centre for Dermatology | Peterborough | Ontario |
Canada | K. Papp Clinical Research | Waterloo | Ontario |
Canada | Carey-Wang - Dermatology & Dermatologic Surgery Center | Westmount | Quebec |
Canada | Wiseman Dermatology Research Inc. | Winnipeg | Manitoba |
Slovakia | Maxderm Dermatovenerologická ambulancia | Bardejov | |
Slovakia | BeneDerma | Bratislava | |
Slovakia | Derma therapy, spol. | Bratislava | |
Slovakia | SKINKLINIK Dermatovenerologická ambulancia | Bratislava | |
Slovakia | AHS Dermatology | Nitra | |
Slovakia | SANARE - Dermatovenerologická ambulancia | Svidník | |
Ukraine | Oleksandrivska Clinical Hospital, Department of Dermatology and Venereology | Kiev | |
Ukraine | LLC MK BLAGOMED, Department of Dermatology | Kyiv | |
Ukraine | Zaporizhzhya Regional Dermatovenereology Clinical Hospital | Zaporizhzhya |
Lead Sponsor | Collaborator |
---|---|
PRCL Research Inc. |
Canada, Slovakia, Ukraine,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of Participants Achieving Psoriasis Area and Severity Index =75% (PASI 75) Improvement | Following 12 weeks of treatment. The Psoriasis Area and Severity Index (PASI) scores the severity of disease on a scale from 0 to 72 (where a score of 72 indicates extreme disease severity). PASI 75 indicates 75% improvement from baseline to Week 12 in the Psoriasis Area and Severity Index | Baseline to week 12 | |
Secondary | Number of Participants With Any Treatment Emergent Adverse Event | Following 12 weeks of treatment | Baseline up to week 18 | |
Secondary | Area Under the Concentration Time Curve (AUC0-t) | Steady state after 12 weeks of treatment | Predose and 1, 2, 4, 8, 336, 672, 1008, 1344 hours post dose, on Day 84 | |
Secondary | Maximum Observed Drug Concentration (Cmax) | Steady state after 12 weeks of treatment | Predose and 1, 2, 4, 8, 336, 672, 1008, 1344 hours post dose, on Day 84 | |
Secondary | Time to Reach Maximum Observed Drug Concentration (Tmax) | Steady state after 12 weeks of treatment | Predose and 1, 2, 4, 8, 336, 672, 1008, 1344 hours post dose, on Day 84 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01194219 -
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
|
Phase 3 | |
Recruiting |
NCT06030076 -
A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis
|
||
Completed |
NCT04263610 -
Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy
|
Phase 4 | |
Completed |
NCT02601469 -
Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Plaque Psoriasis
|
Phase 2 | |
Completed |
NCT05600036 -
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis
|
Phase 2 | |
Completed |
NCT05375955 -
A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.
|
Phase 2 | |
Not yet recruiting |
NCT05036889 -
A 16-week Randomized Evaluation of the Impact of Mind.Px Application on Response to Biologic Treatment in Patients Suffering From Plaque Psoriasis Through Clinical Utility and Health Outcomes.
|
N/A | |
Completed |
NCT04603027 -
A Phase 2 Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis
|
Phase 2 | |
Completed |
NCT03638258 -
The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis
|
Phase 2 | |
Completed |
NCT02881346 -
Efficacy and Tolerability of Enstilar® in Daily Practice
|
||
Recruiting |
NCT02611349 -
Study to Evaluate the Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis
|
Phase 3 | |
Completed |
NCT02251678 -
Evaluate the Effect of Elimune Capsules
|
Phase 1 | |
Completed |
NCT01987843 -
Dose-finding Study of MT-1303 in Subjects With Moderate to Severe Chronic Plaque Psoriasis
|
Phase 2 | |
Terminated |
NCT01708629 -
Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
|
Phase 3 | |
Completed |
NCT01230138 -
Pivotal Efficacy and Safety Registration Trial of FP187 in Moderate to Severe Plaque Psoriasis
|
Phase 2 | |
Withdrawn |
NCT00747032 -
To Demonstrate the Superior Efficacy of NYC 0462 Ointment Over That of the Placebo in the Treatment of Plaque Psoriasis
|
Phase 3 | |
Completed |
NCT00581100 -
Effects of Etanercept on Nail Psoriasis and Plaque Psoriasis
|
Phase 4 | |
Suspended |
NCT01228656 -
Effectiveness of Association Mometasone Furoate 0.1% and Salicylic Acid 5% Compared With Mometasone Furoate
|
Phase 2 | |
Completed |
NCT00540618 -
A Phase II Study of MEDI-507, Administered by Injection to Adults With Psoriasis
|
Phase 2 | |
Completed |
NCT05442788 -
A Study of HB0017 in Patients With Moderate to Severe Plaque Psoriasis
|
Phase 1 |